Compare ORIC & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIC | HQH |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | 111 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | ORIC | HQH |
|---|---|---|
| Price | $13.74 | $23.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $19.73 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 222.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ 1.09 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $16.20 |
| 52 Week High | $14.93 | $24.85 |
| Indicator | ORIC | HQH |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 56.87 |
| Support Level | $13.12 | $18.57 |
| Resistance Level | $13.97 | N/A |
| Average True Range (ATR) | 0.63 | 0.44 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 52.96 | 36.02 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.